| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Lauroyl-L-carnitine chloride functions as a cell permeabilizing agent and absorption enhancer. As a cationic surfactant, it can interact with cell membranes, increasing their permeability. It does not have a specific biological receptor target but is used as a tool to facilitate the delivery of other molecules into cells.
|
|---|---|
| ln Vitro |
In vitro, Lauroyl-L-carnitine chloride has been used to permeabilize porcine enterocytes, allowing for the delivery of the polar fluorescent probe lucifer yellow. This demonstrates its utility as a cell permeabilization agent in laboratory settings. Specific IC50 values or detailed mechanistic data are not reported, as its primary use is as a research reagent rather than a therapeutic compound.
|
| ln Vivo |
Lauroyl-L-carnitine chloride is not used as a therapeutic compound in vivo. It is a research reagent used for cell permeabilization and as an absorption enhancer. It may be used in ex vivo studies to facilitate the delivery of compounds into cells or tissues, but it is not administered systemically for therapeutic purposes.
|
| Enzyme Assay |
The cell permeabilization activity of Lauroyl-L-carnitine chloride is assessed using fluorescent probe uptake assays. Cells (e.g., porcine enterocytes) are treated with the compound and then incubated with a polar fluorescent probe such as lucifer yellow. The uptake of the probe into the cells is measured by fluorescence microscopy or flow cytometry, indicating the extent of cell permeabilization.
|
| Cell Assay |
For cellular studies, appropriate cell types (e.g., enterocytes) are cultured in suitable media. Lauroyl-L-carnitine chloride is added to the culture medium at various concentrations to permeabilize the cells. The compound is typically dissolved in a suitable solvent. Cell viability is assessed to ensure that permeabilization does not lead to significant cytotoxicity. The compound has a molecular formula of C19H38ClNO4 and a molecular weight of 379.96 g/mol.
|
| Animal Protocol |
Lauroyl-L-carnitine chloride is not used in animal studies as a therapeutic compound. It is a research reagent used in ex vivo or in vitro studies for cell permeabilization.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Lauroyl-L-carnitine chloride are not applicable as it is not a therapeutic compound. The compound has a molecular formula of C19H38ClNO4 and a molecular weight of 379.96 g/mol. It should be stored at 4°C, sealed and away from moisture.
|
| Toxicity/Toxicokinetics |
Lauroyl-L-carnitine chloride is a chemical reagent and should be handled with appropriate safety precautions. It may cause irritation to skin, eyes, and respiratory tract. Standard laboratory safety practices should be followed, including the use of gloves, eye protection, and proper ventilation.
|
| References |
[1]. Fu, Ling, et al. An oral pharmaceutical composition of a peptide amide compound (I, compound A). The present invention further relates to a method for preparing an oral pharmaceutical composition, and the use of the oral pharmaceutical composition in preparing a drug for treating diseases or conditions related to the κ-opioid receptor. China, WO2021185265. 2021-09-23
[2]. Ling Fu, et al. Oral pharmaceutical composition. Patent WO2021185265A1. |
| Additional Infomation |
Lauroyl-L-carnitine chloride is an acylcarnitine and cationic surfactant used as a cell permeabilization agent and absorption enhancer. Molecular formula: C19H38ClNO4, molecular weight: 379.96 g/mol. No clinical applications exist. For research use only.
|
| Molecular Formula |
C19H38CLNO4
|
|---|---|
| Molecular Weight |
379.96
|
| Exact Mass |
379.248
|
| CAS # |
6919-91-1
|
| Related CAS # |
Lauroyl-L-carnitine-d3 chloride;2687960-76-3;Lauroyl-L-carnitine-d9 chloride;2245711-25-3;Lauroyl-L-carnitine-d3 hydrochloride;1297271-52-3
|
| PubChem CID |
91886502
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
25
|
| Complexity |
350
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[Cl-].O(C(CCCCCCCCCCC)=O)[C@H](CC(=O)O)C[N+](C)(C)C
|
| InChi Key |
PDBBUDRTWRVCFN-UNTBIKODSA-N
|
| InChi Code |
InChI=1S/C19H37NO4.ClH/c1-5-6-7-8-9-10-11-12-13-14-19(23)24-17(15-18(21)22)16-20(2,3)4;/h17H,5-16H2,1-4H3;1H/t17-;/m1./s1
|
| Chemical Name |
[(2R)-3-carboxy-2-dodecanoyloxypropyl]-trimethylazanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~131.6 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (3.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6319 mL | 13.1593 mL | 26.3186 mL | |
| 5 mM | 0.5264 mL | 2.6319 mL | 5.2637 mL | |
| 10 mM | 0.2632 mL | 1.3159 mL | 2.6319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
